Gland Pharma Ltd., a pharmaceutical company, experienced a surge in its stock prices following the approval of its drug application by the U.S. Food and Drug Administration (FDA). The FDA granted approval for the company’s abbreviated new drug application for Fomepizole injectable, an antidote for ethylene glycol and methanol poisoning. This approval boosted investor confidence, leading to an 8.57% increase in the company’s shares. Gland Pharma’s successful drug application highlights its commitment to developing essential medications and addressing critical healthcare needs. The FDA approval not only validates the safety and efficacy of Fomepizole injectable but also opens doors for the company to expand its market presence and cater to a broader patient population in need of this antidote.
Global News and Digital Insights
for the Healthcare Industry
Menu
